CU Anschutz Awarded $120M DARPA Contract to Validate Hemorrhage Therapeutics in Clinical Trials
- University of Colorado Anschutz receives up to $120 million over three years from DARPA to independently verify and validate emerging hemorrhage treatments and diagnostics for human clinical trials and FDA review.
- CU Anschutz will evaluate as many as 11 products over three years, including novel blood products, oxygen carriers, and diagnostic technologies, serving as an external research site for DARPA's RAPIID program.
- UCHealth University of Colorado Hospital and the ATLAS Research Program will support clinical trial execution as validated technologies advance toward regulatory approval.
Operational Impact
CU Anschutz's ATLAS Research Program and UCHealth clinical trial infrastructure will execute Phase 1–2 validation studies for up to 11 hemorrhage products, creating sustained clinical trial demand and establishing the campus as a preferred site for DARPA-sponsored therapeutic development.
Source: PR Newswire pharma category RSS